# A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

> clinical trial · VERIFIED · 2026-07-13

Status: RECRUITING · Sponsor: Hoffmann-La Roche · Condition: Non-Small Cell Lung Cancer

- Company: Hoffmann-La Roche
- Sector: Non-Small Cell Lung Cancer
- Primary source: https://clinicaltrials.gov/study/NCT05789082

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.